Manufacturing News of Note—Merck & Co., Just - Evotech to share specialized biologics space; DBL buys GSK cream line in Bangladesh

A closeup of a stock market ticker

>  Merck & Co will pay Seattle-based Just – Evotec Biologics $15 million upfront to use excess capacity at a biologics facility the company is building in Redmond, Washington. Story

> GBA Group Pharma has doubled the size of its clinical supply facilities in Vienna ahead of Brexit, it says. Release

> DBL Pharmaceuticals says it has a deal to acquire the cream and ointment manufacturing line of GlaxoSmithKline Bangladesh with plans of reintroducing the products that GSK made there before exiting the country. Story

> Helixmith Co. and Genopis say they will launch a contract manufacturing operation to manufacture plasmid DNA for clients. Release

> Medivant Health is building a 33,000-square-foot generic drug manufacturing facility in Chandler, Arizona, to address drug shortages. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.